Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep 5:18:e00633.
doi: 10.1016/j.idcr.2019.e00633. eCollection 2019.

Ceftriaxone use in brucellosis: A case series

Affiliations
Case Reports

Ceftriaxone use in brucellosis: A case series

Daniah F Fatani et al. IDCases. .

Abstract

Background: Brucellosis is a zoonotic disease caused by Brucella spp. It can be either uncomplicated or complicated when it disseminates to other organs. Treatment for brucellosis involves a combination of at least two antibiotics, or more in complicated brucellosis. Limited data exist on the use of ceftriaxone in the clinical setting. Therefore, we present patient cases in which ceftriaxone was used in brucellosis treatment regimen.

Methods: Patients with documented brucellosis from January 2008 to December 2018 were evaluated for the use of ceftriaxone for treatment in King Abdulaziz Univeristy Hospital, Jeddah, Saudi Arabia. Patients' data were evaluated retrospectively and are described.

Results: Out of 94 treated brucellosis patients, six patients received ceftriaxone 2 g IV every 12 h for therapy for varied durations. Four had neurobrucellosis, one had Brucella epididymo-orchitis and one had uncomplicated brucellosis. All six patients experienced clinical cure, though one neurobrucellosis patient had complications and one had ceftriaxone stopped after one week of therapy due to presumed antibiotic-induced fever.

Conclusion: Ceftriaxone represents a reasonable option for the treatment of complicated brucellosis when added to the initial regimen at a dose of 2 g IV every 12 h.

Keywords: Brucella; Brucellosis; Cases; Ceftriaxone; Saudi Arabia; Zoonotic infection.

PubMed Disclaimer

Figures

Image 1
Image 1
Brain magnetic resonance imaging of patient case 1 at baseline on T1 post contrast cuts showing multiple enhancing dural based lesions in both upper frontal lobes at different levels.
Image 2
Image 2
Brain magnetic resonance imaging of patient case 1 after three weeks of treatment.
Image 3
Image 3
Spinal magnetic resonance imaging of patient case 4 on T1 post contrast on sagittal and axial views showing enhancing cauda equina nerve roots.

Similar articles

Cited by

References

    1. Corbel M.J. World Health Organization; 2006. Brucellosis in humans and animals.
    1. Centers for Disease Control and Prevention . 2017. Brucellosis reference guide: exposures, testing and prevention.
    1. Dean A.S., Crump L., Greter H., Schelling E., Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis. 2012;6:e1865. - PMC - PubMed
    1. Rubach M.P., Halliday J.E., Cleaveland S., Crump J.A. Brucellosis in low-income and middle-income countries. Curr Opin Infect Dis. 2013;26:404–412. - PMC - PubMed
    1. Tuon F.F., Cerchiari N., Cequinel J.C., Droppa E.E.H., Moreira S.D.R., Costa T.P. Guidelines for the management of human brucellosis in the State of Paraná, Brazil. Rev Soc Bras Med Trop. 2017;50:458–464. - PubMed

Publication types

LinkOut - more resources